US 12,241,053 B2
Modulation of novel immune checkpoint targets
Vijay K. Kuchroo, Boston, MA (US); Ana C. Anderson, Boston, MA (US); Asaf Madi, Boston, MA (US); Norio Chihara, Boston, MA (US); Aviv Regev, Cambridge, MA (US); and Meromit Singer, Cambridge, MA (US)
Assigned to THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US); THE BROAD INSTITUTE, INC., Cambridge, MA (US); and MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US)
Appl. No. 15/767,074
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US); The Broad Institute, Inc., Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
PCT Filed Oct. 7, 2016, PCT No. PCT/US2016/056177
§ 371(c)(1), (2) Date Apr. 9, 2018,
PCT Pub. No. WO2017/069958, PCT Pub. Date Apr. 27, 2017.
Claims priority of provisional application 62/239,548, filed on Oct. 9, 2015.
Prior Publication US 2019/0255107 A1, Aug. 22, 2019
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6881 (2018.01)
CPC C07K 14/705 (2013.01) [A61K 39/39 (2013.01); A61K 39/4611 (2023.05); A61K 39/464492 (2023.05); A61P 31/04 (2018.01); A61P 31/12 (2018.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 15/62 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6881 (2013.01); A61K 2239/31 (2023.05); A61K 2239/57 (2023.05); C12N 2501/2327 (2013.01); C12N 2510/00 (2013.01)] 17 Claims
 
1. An isolated immune cell genetically modified to (a) downregulate or abolish expression or activity of a gene encoding protein C receptor (PROCR) and one or more genes selected from the group consisting of genes encoding PRDMI, c-MAF, and Podoplanin (PDPN); or (b) comprise an agent capable of inducibly downregulating expression or activity of a gene encoding PROCR and one or more genes encoding PRDMI, c-MAF, and PDPN.